Article Versions Notes

van der Lee DI, Koutsoumpli G, Reijmers RM, Honders MW, de Jong RCM, Remst DFG, Wachsmann TLA, Hagedoorn RS, Franken KLMC, Kester MGD, et al. An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML. Cancers. 2021; 13(21):5390. https://doi.org/10.3390/cancers13215390

van der Lee, Dyantha I., Georgia Koutsoumpli, Rogier M. Reijmers, M. Willy Honders, Rob C. M. de Jong, Dennis F. G. Remst, Tassilo L. A. Wachsmann, Renate S. Hagedoorn, Kees L. M. C. Franken, Michel G. D. Kester, and et al. 2021. "An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML" Cancers 13, no. 21: 5390. https://doi.org/10.3390/cancers13215390

van der Lee, D. I., Koutsoumpli, G., Reijmers, R. M., Honders, M. W., de Jong, R. C. M., Remst, D. F. G., Wachsmann, T. L. A., Hagedoorn, R. S., Franken, K. L. M. C., Kester, M. G. D., Harber, K. J., Roelofsen, L. M., Schouten, A. M., Mulder, A., Drijfhout, J. W., Veelken, H., van Veelen, P. A., Heemskerk, M. H. M., Falkenburg, J. H. F., & Griffioen, M. (2021). An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML. Cancers, 13(21), 5390. https://doi.org/10.3390/cancers13215390